Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca will buy preclinical TCR-T cell therapy developer Neogene Therapeutics for up to 320 million dollars, the British-Swedish pharma said Tuesday. The…
AstraZeneca is paying up to 320 million dollars for Dutch biotech Neogene Therapeutics, adding TCR-T cell therapy capabilities for solid tumors driven by…
As of 29 July 2025: NT-125 (autologous, fully-individualised, multi-specific neoantigen-targeting TCR-T; Phase I, EudraCT 2021-006406-73, FPCD Q2…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
AstraZeneca agreed to acquire all outstanding equity of Neogene Therapeutics for up to $320M, including $200M on closing and up to $120M in contingent and non-contingent additional consideration. The deal added next-generation TCR-T discovery, development and manufacturing capabilities including individualized therapies and shared-neoantigen TCRs targeting mKRAS and mTP53. Closed Q1 2023. POST-CLOSE (as of AstraZeneca's H1/Q2 2025 results, 29 Jul 2025): AZ discontinued the lead Neogene asset NT-125 -- a fully-individualised, multi-specific neoantigen TCR-T (Phase I, EudraCT 2021-006406-73, first patient dosed Q2 2023) -- 'due to strategic portfolio prioritisation,' removing it from Phase I. The broader Neogene TCR-T platform was retained: AZ's pipeline still carries the shared-neoantigen programs central to the original rationale -- NT-112 (TGFBR2-KO armored TCR-T targeting KRAS G12D) and NT-175 (TGFBR2-KO armored TCR-T targeting TP53 R175H), both in solid tumours. The capability/platform thesis substantially holds; the lead individualized asset did not survive portfolio prioritisation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Neogene Therapeutics B.V. (this deal) | 2022 | $320M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Oncology deals